سیاست های تأمین تجهیزات واکسن اطفال: مشکل مونوسونیت
|کد مقاله||سال انتشار||تعداد صفحات مقاله انگلیسی||ترجمه فارسی|
|17010||2011||9 صفحه PDF||سفارش دهید|
نسخه انگلیسی مقاله همین الان قابل دانلود است.
هزینه ترجمه مقاله بر اساس تعداد کلمات مقاله انگلیسی محاسبه می شود.
این مقاله تقریباً شامل 7422 کلمه می باشد.
هزینه ترجمه مقاله توسط مترجمان با تجربه، طبق جدول زیر محاسبه می شود:
|شرح||تعرفه ترجمه||زمان تحویل||جمع هزینه|
|ترجمه تخصصی - سرعت عادی||هر کلمه 90 تومان||11 روز بعد از پرداخت||667,980 تومان|
|ترجمه تخصصی - سرعت فوری||هر کلمه 180 تومان||6 روز بعد از پرداخت||1,335,960 تومان|
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : Omega, Volume 39, Issue 6, December 2011, Pages 589–597
Vaccination against infectious disease is an extremely important public health endeavor. Yet, in the past 40 years, the manufacture of pediatric vaccines has become less profitable due to rising costs and limited demand, inducing many pharmaceutical companies to leave the market. To ensure the safe, secure, and reliable provision of vaccines, the economic interests of the vaccine industry must be considered by public health policy makers. The monopsonistic market power of the federal government uniquely positions it to significantly influence the pediatric vaccine market by negotiating contractual agreements that increase the vaccine manufacturers’ financial incentives to remain in the market. The Monopsonist Vaccine Formulary Pricing and Purchasing Problem (MVF3P) is introduced, which seeks pediatric vaccine prices and purchase quantities that ensure a birth cohort is fully immunized according to the recommended childhood immunization schedule at an overall minimum system cost while also ensuring that vaccine manufacturers each attain a reservation profit level. The practical value of MVF3P is demonstrated by analyzing and assessing pricing and purchasing policies that the Centers for Disease Control could adopt in attempting to actively manage the long-term provision of pediatric vaccines.
Vaccination is one of the most important and successful public health endeavors in human history, profoundly reducing the number of mortalities caused by infectious diseases  and . In the United States, the incidence of many childhood diseases has dramatically decreased, even as the number of vaccine-preventable diseases has increased . Yet, by some measures the pediatric vaccine industry is quite fragile . To ensure the safe, secure, and reliable provision of vaccines, the economic interests of the vaccine industry must be considered by public health policy makers. The United States pediatric vaccine industry consists of a relatively small number of pharmaceutical companies engaged in the research, development, manufacture, and distribution of pediatric vaccines. Participation in the vaccine industry is a difficult, costly, risky, and most importantly, voluntary enterprise. All pediatric vaccines distributed in the United States are manufactured by privately held companies, with no obligation to sustain or initiate the production of pediatric vaccines, regardless of the importance of such vaccines to public health  and . Over the past 40 years, the manufacture of pediatric vaccines has become less profitable due to rising costs and limited demand, inducing many pharmaceutical companies to exit the market  and . As of 2010, just six pharmaceutical companies manufacture vaccines for young children, three of which manufacture only one pediatric vaccine . The contraction of the pediatric vaccine market negatively impacts the provision of vaccines. When a vaccine is produced by a small number of manufacturers, production problems create immediate, acute shortages . In order to ensure adequate immunization coverage levels, a robust vaccine industry is vital to the nation's public health and well being. A substantial number of public health policy experts have highlighted factors that would assist in sustaining the current supply of vaccines, as well as encourage the development of new vaccines , , , ,  and . Typically, recommendations concerning the vaccine industry's robustness involve financial incentives. For example, Hinman  suggests pricing a vaccine in advance based on its estimated social value. McGuire  offers an economic model to facilitate the determination of such prices, reporting that while vaccines have high social value (see Zhou et al.  for a full analysis concerning the economic benefit of vaccines to society), the vaccine manufacturers do not receive appropriate financial incentives for participation in the market. Many public health experts contend that vaccine manufacturers should earn higher returns on their investments in order to sustain and expand the production of vaccines , , , ,  and . The monopsonistic market power of the federal government uniquely positions it to significantly influence the pediatric vaccine market by negotiating contractual agreements that increase the vaccine manufacturers’ financial incentives to enter or remain in the market. Pediatric vaccines purchased at the public-sector price, as negotiated by federal government officials at the Centers for Disease Control and Prevention (CDC), account for approximately 57% (by volume) of total pediatric vaccine purchases  and . In the United States, the CDC acts as the primary federal public health organization responsible for setting pediatric immunization policy. Based on recommendations from the Advisory Committee on Immunization Practices (ACIP), the CDC annually publishes a Recommended Childhood Immunization Schedule (RCIS) (see Fig. 1 from ) that provides specific guidance regarding the effective control of vaccine-preventable diseases, to include the appropriate periodicity and dosage requirements for each pediatric vaccine. The RCIS serves as the fundamental force driving market demand ; vaccine purchasers buy vaccines in order to fully immunize children in accordance with the RCIS. The CDC also maintains a list of acceptable pediatric vaccines (i.e., licensed by the Food and Drug Administration (FDA) ) and negotiates discounted prices at which federal, state, and local governments can purchase the vaccines. A model that addresses the short term need to satisfy the RCIS at minimum economic cost while accounting for long-term concerns regarding the vaccine industry's viability provides value to the public health community (specifically, the CDC) and is the focus of this research. Full-size image (64 K) Fig. 1. United States 2010 Recommended Childhood Immunization Schedule (through age 6). Figure options Operations research methods have been applied to the analysis of the United States pediatric vaccine market. Prior research has mostly addressed the selection of an optimal vaccine formulary (i.e., a set of vaccines stocked to satisfy the immunization needs for a population cohort, as defined by a given set of immunization requirements) that satisfies a RCIS at minimum cost ,  and  (from the perspective of a vaccine purchaser) or the determination of optimal vaccine prices , , ,  and  (from the perspective of a vaccine manufacturer). Weniger et al.  introduce an integer program (IP) model to aid health care decision makers in determining a vaccine formulary that minimizes the cost to fully immunize a child according to a given childhood immunization schedule. Jacobson et al.  present a full technical description of the model introduced by Weniger et al. . Hall et al.  introduce the general vaccine formulary selection problem, providing fundamental insights into the structure of problems concerning minimum cost satisfaction of a childhood immunization schedule. Sewell et al.  adopt a ”reverse engineering” scheme involving a bisection algorithm to compute a vaccine's maximum inclusion price (i.e., the maximum price at which a vaccine is selected to be part of the lowest overall cost formulary). Sewell and Jacobson  present a full technical description of the methods in Sewell et al. . Similar efforts are seen in Jacobson et al.  and . Robbins et al.  present a method to optimally price a pediatric vaccine so as to maximize a vaccine manufacturer's expected revenue given an uncertain cost parameter. While these efforts provide analysis tools to help one group of stakeholders in the pediatric vaccine market make decisions, no study has presented a comprehensive approach in which the interests of all stakeholders in the market are simultaneously considered. This research effort addresses the issue of the pediatric vaccine industry's continuing viability from the perspective of the monopsonistic federal government. The fundamental premise of the analysis is the supposition that the altruistic CDC desires to negotiate pediatric vaccine prices and determine purchase quantities in order to minimize the vaccine system's delivery costs while ensuring that the pharmaceutical companies manufacturing the pediatric vaccines each earn a profit that induces them to remain in the market. The operations research approach presented in this paper defines the Monopsonist Vaccine Formulary Pricing and Purchasing Problem (MVF3P) mixed integer nonlinear program (MINLP) model, which minimizes the weighted sum of the cost to fully immunize a birth cohort according to a given childhood immunization schedule. The model determines optimal vaccine prices and purchase quantities while ensuring that each vaccine manufacturer earns at least a particular amount of profit, with vaccine production quotas, capacities, and price caps respected. The MVF3P MINLP model can be used to design a pricing and purchasing policy for the CDC that establishes a sustainable and stable capital investment environment in which the reliable provision of the pediatric vaccines (so essential to public health) can occur. The paper is organized as follows. Section 2 presents the MINLP model formulation for the optimization problem MVF3P that determines the set of pediatric vaccine formularies and attendant component vaccine prices and quantities that should be used to satisfy a given childhood immunization schedule for an entire birth cohort. The model minimizes overall system cost while ensuring a sustainable market environment for vaccine manufacturers. Section 3 presents the computational complexity of MVF3P. Section 4 reports the computational results of applying the MVF3P MINLP model to the analysis of CDC pricing and purchasing policies; optimal pediatric vaccine prices and purchase quantities for the current United States pediatric vaccine market are reported. Section 5 provides concluding comments and directions for future research.
نتیجه گیری انگلیسی
This paper describes MVF3P, which seeks pediatric vaccine prices and purchase quantities that ensure a given birth cohort is fully immunized according to a particular childhood immunization schedule at an overall minimum cost while also ensuring vaccine manufacturers each attain an appropriate level of profit. Although MVF3P was shown to be NP-hard, real-world problem instances are sufficiently small and are solvable in a reasonable amount of time using commercial software. The practical value of the proposed MINLP model was demonstrated by analyzing and assessing different pricing and purchasing policies that the CDC could adopt in attempting to actively manage the long-term provision of pediatric vaccines. Public health policies made by the CDC greatly influence the capital investment environment within the United States pediatric vaccine market. Current policies regarding vaccine prices and purchase quantities affect pharmaceutical companies’ expectations concerning future profit for vaccines still in the developmental stage. An expectation of excessive price control suppresses capital investment in the research and development of new vaccines as pharmaceutical companies see that alternative investment vehicles would provide a higher return on investment. The necessary revenue streams for sustaining the pharmaceutical industry's participation in the vaccine market would be absent, stifling innovation, and ultimately leading to an unsafe environment for the reliable provision of vaccines. The CDC's vaccine pricing and purchasing policies are critical to the long-term success of public immunization programs. Indeed, the CDC has a delicate task: it must balance the division of the net benefit (i.e., economic vs. social surplus) received from the sale and the use of the vaccine between the vaccine manufacturer and the purchaser/consumer. The monopsonistic federal government is well positioned to achieve an appropriate balance between immunization coverage levels (facilitated by lower prices) and appropriate investment in research and development (facilitated by higher prices). The MVF3P MINLP model provides a mathematical framework by which public health policy practitioners at the CDC can develop and analyze any number of potential policies that seek to address this balance and best provide for the common good. An important implicit assumption regarding vaccine procurement policy affects interpretation of the MVF3P model results. Currently, total industry vaccine purchases are driven by the ordering behavior of government (e.g., state and county) health care organizations and providers that purchase vaccines using funds from the Vaccines For Children program, the 317 program, and/or state and local government programs ,  and . Consequently, the CDC does not have direct procurement control over specific pediatric vaccine purchases nor can the CDC dictate which formulary a particular organization or provider should use to satisfy the RCIS. However, MVF3P model results can certainly facilitate a more informed discussion amongst all stakeholders involved, so that policy decisions work toward a common holistic good. Several potentially important economic factors that could impact the overall cost of immunization are not included in this study. The exclusion of such factors is due primarily to the lack of data or economic models regarding them. Some factors are important as an issue of differentiation between manufacturer products. For example, vaccine efficacy, adverse reaction frequency, shelf life, and thermal storage requirements  could all be factors distinguishing two vaccines and may influence the decision on which vaccine formularies to purchase. In addition to product differentiation, this study does not address potential cost savings associated with reduced inventory handling resulting from the reduction in the number of separate vaccines included in lower cost formularies. Lastly, extraimmunization, brand loyalty, volume discounting, risk of supply interruptions, and formulary inertia are not addressed due to the difficulty in quantifying economic model parameters describing them.